Gene variants predict treatment success for alcoholism medication – 4
Narrator: This is NIH Health Matters. I’m Joe Balintfy. Results of a research study show subjects with two different genotypes responded better to an experimental treatment for alcoholism.
Litten: It was like it was an interaction.
Narrator: Dr. Raye Litten of the National Institute on Alcohol Abuse and Alcoholism says, individuals who possessed both LL and TT gene variants had more pronounced effects of the drug.
Litten: In fact it appears that the effects by having both the LL and TT you can almost double your effect size with that combination.
Narrator: The drug is ondansetron and is currently used to treat nausea and vomiting. For more on how it has shown success as an alcoholism medication, visit www.niaaa.nih.gov. Health Matters is produced by the National Institutes of Health, part of the U.S. Department of Health and Human Services.
About NIH Radio
NIH Radio offers free audio news programs from the National Institutes of Health, your reliable source for health information.
All NIH Radio content is in the public domain and can be used without charge or restriction provided that it is not used to misrepresent our agency nor used to suggest we endorse any private organization, product, or service.
NIH Radio is a service of the Office of Communications & Public Liaison.